Skip to main content

Angioedema following Dipeptidyl Peptidase IV (DPP IV) Inhibitors and Angiotensin Converting Enzyme (ACE) Inhibitors Use: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product
    angiotensin-converting enzyme (ACE) inhibitor
    dipeptidyl peptidase-IV (DPP-IV) inhibitor
    Health Outcome(s)

    This report examined angioedema among new users of dipeptidyl peptidase IV (DPP IV) inhibitors and/or angiotensin converting enzyme (ACE) inhibitors in the Mini-Sentinel Distributed Database (MSDD). This analysis includes two reports:

    • Report 1: We examined angioedema among individuals with incident exposure to either DPP IV inhibitors or ACE inhibitors.
    • Report 2: We examined angioedema among individuals with concomitant exposures to both DPP IV inhibitors and ACE inhibitors.

    The study period includes data from October 16, 2006 to December 31, 2012. We distributed this request to 18 Data Partners on December 20, 2013.

    Additional Details
    FDA Center
    Time Period
    October 16, 2006 - December 31, 2012
    Analysis Type
    Population / Cohort
    Individuals 20 years of age and older
    Data Sources
    Mini-Sentinel Distributed Database (MSDD)